Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials

被引:2340
作者
Sylvester, RJ [1 ]
van der Meijden, APM
Oosterlinck, W
Witjes, JA
Bouffioux, C
Denis, L
Newling, DWW
Kurth, K
机构
[1] EORTC Data Ctr, Brussels, Belgium
[2] Jeroen Bosch Hosp, Dept Urol, Shertogenbosch, Netherlands
[3] State Univ Ghent Hosp, Dept Urol, B-9000 Ghent, Belgium
[4] Radboud Univ, Med Ctr, Dept Urol, Nijmegen, Netherlands
[5] CHU Sart Tilman, Dept Urol, B-4000 Liege, Belgium
[6] Middelheim Hosp, Dept Urol, Antwerp, Belgium
[7] Free Univ Amsterdam, Med Ctr, Dept Urol, Amsterdam, Netherlands
[8] Acad Med Ctr, Dept Urol, Amsterdam, Netherlands
关键词
superficial bladder cancer; prognostic factors; recurrence; progression; cystectomy; prediction;
D O I
10.1016/j.eururo.2005.12.031
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection. Methods: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials. Results: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%. Conclusions: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:466 / 477
页数:12
相关论文
共 48 条
[1]  
Allard P, 1998, BRIT J UROL, V81, P692
[2]   Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer:: prognostic factors for time to recurrence and progression [J].
Andius, P ;
Holmäng, S .
BJU INTERNATIONAL, 2004, 93 (07) :980-984
[3]   The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma [J].
Bernardini, S ;
Billerey, C ;
Martin, M ;
Adessi, GL ;
Wallerand, H ;
Bittard, H .
JOURNAL OF UROLOGY, 2001, 165 (01) :42-46
[4]   Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].
Böhle, A ;
Jocham, D ;
Bock, PR .
JOURNAL OF UROLOGY, 2003, 169 (01) :90-95
[5]   INTRAVESICAL ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL TRANSITIONAL-CELL BLADDER-CARCINOMA - RESULTS OF 2 EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER RANDOMIZED TRIALS WITH MITOMYCIN-C AND DOXORUBICIN COMPARING EARLY VERSUS DELAYED INSTILLATIONS AND SHORT-TERM VERSUS LONG-TERM TREATMENT [J].
BOUFFIOUX, C ;
KURTH, KH ;
BONO, A ;
OOSTERLINCK, W ;
KRUGER, CB ;
DEPAUW, M ;
SYLVESTER, R ;
DENIS, L ;
NEWLING, D ;
HALL, R ;
BRESSEL, M ;
CASSELMAN, J ;
SMITH, P ;
ROBINSON, M ;
KEUPPENS, F ;
TOLLEY, D ;
JAKSE, G ;
BOLLACK, C ;
VERGISON, B ;
HOEKSTRA, W ;
DASILVA, FC ;
GROEN, J ;
RICHARDS, B ;
PAVONEMACALUSO, M ;
VANDERMEIJDEN, A ;
ZWARTENDIJK, H ;
JACOBI, G ;
VANCAUBERG, R ;
SCHRODER, F ;
HIRDES, D ;
LEISINGER, H ;
RIEDL, H ;
LUDWIG, P ;
ROOZENDAAL, K ;
MARECHAL, L ;
VANAUBEL, O ;
CONSIDINE, J ;
DEBRUYNE, F ;
CARREIRA, F ;
DEWALL, D ;
MENSINK, H ;
VIGGIANO, G .
JOURNAL OF UROLOGY, 1995, 153 (03) :934-941
[6]   ADJUVANT CHEMOTHERAPY OF RECURRENT SUPERFICIAL TRANSITIONAL CELL-CARCINOMA - RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING INTRAVESICAL INSTILLATION OF THIOTEPA, DOXORUBICIN AND CISPLATIN [J].
BOUFFIOUX, C ;
DENIS, L ;
OOSTERLINCK, W ;
VIGGIANO, G ;
VERGISON, B ;
KEUPPENS, F ;
DEPAUW, M ;
SYLVESTER, R ;
CHEUVART, B .
JOURNAL OF UROLOGY, 1992, 148 (02) :297-301
[7]   ANALYSIS OF THE PROBABILITY AND RISK OF CAUSE-SPECIFIC FAILURE [J].
CAPLAN, RJ ;
PAJAK, TF ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (05) :1183-1186
[8]   PROGNOSTIC FACTORS IN SUPERFICIAL BLADDER-TUMORS - A STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER - GENITOURINARY TRACT CANCER COOPERATIVE GROUP [J].
DALESIO, O ;
SCHULMAN, CC ;
SYLVESTER, R ;
DEPAUW, M ;
ROBINSON, M ;
DENIS, L ;
SMITH, P ;
VIGGIANO, G ;
SOLOWAY, MS .
JOURNAL OF UROLOGY, 1983, 129 (04) :730-733
[9]   Significance of bladder neck involvement on progression in superficial bladder cancer [J].
Fujii, Y ;
Fukui, I ;
Kihara, K ;
Tsujii, T ;
Ishizaka, K ;
Kageyama, Y ;
Kawakami, S ;
Oshima, H .
EUROPEAN UROLOGY, 1998, 33 (05) :464-468
[10]   T1G3 bladder cancer: Conservative management or cystectomy? [J].
Gattegno, B .
EUROPEAN UROLOGY, 2004, 45 (04) :399-400